Business Wire

MERCANS

23.1.2024 15:01:31 CET | Business Wire | Press release

Share
Mercans’ G2N Nova Solves Global Payroll Data Privacy Challenges

Mercans continues to disrupt the global payroll industry and solidify its leadership position by rolling out exciting new features to its flagship, G2N Nova payroll engine. The recently launched features include game-changing technology and address some of the biggest challenges of global payroll, including international data privacy compliance and processing latency limitations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123634878/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mercans Unveils New Updates to Its Power-Packed Payroll Engine G2N Nova (Graphic: AETOSWire)

Mercans’ G2N Nova leverages groundbreaking stateless application architecture to enable completely anonymous payroll processing. This unprecedented technological approach enables processing gross-to-net payrolls without any sensitive Personal Identifiable Information (PII) ever being passed from clients to Mercans’ G2N Nova global payroll application.

The stateless application architecture has never before been successfully deployed in the global payroll industry, and G2N Nova, is the only payroll engine that is able to generate 100% accurate gross-to-net calculations for 100+ countries. And that’s not all, it does so through a single, native platform in real-time without accessing or storing any identifiable information related to employees. This evidently innovative, payroll technology solution completely overcomes the complex data privacy compliance requirements, as confidential employee data never leaves the clients’ systems and is not needed by G2N Nova for gross-to-net payroll calculations. Thus, proving its technological prowess and independence.

Additionally, this approach is a game-changer for the industry because data breaches and ransomware attacks have created concerns about data security and privacy in the payroll sector. These concerns have been significant hurdles for companies trusting external service or software providers for international payroll processing. G2N Nova’s stateless app architecture eliminates these concerns entirely. Clients’ PII never leaves their data centers and payroll-related information used by G2N Nova is completely anonymized.

G2N Nova upgrade also includes a ground-breaking Continuous Calc feature that fundamentally changes how payrolls are processed. Until now, all payrolls had to go through a multi-step payroll processing cycle. G2N Nova breaks this legacy paradigm and introduces real-time net pay. The Continuous Calc feature maintains full gross-to-net values for each employee in real-time and automatically updates the net pay amounts of employees whenever there is an update to an employee’s record. This feature, thus, eliminates the need to wait for a payroll processing cycle to be completed to determine an employee’s net pay for a period. The gross-to-net values for all employees will be always available in real-time.

In addition, the new version of G2N Nova lays a foundation for incorporating blockchain technology into payroll processes, allowing instantaneous and 100% tamper-proof verification of payroll calculations and payments using blockchain technology. Blockchain will create a permanent, unchangeable record of real-time record of all payroll transactions and amounts — so no one can alter or remove it. This revolutionary approach, thus, solidifies the foundation for third parties, including financial institutions, tax authorities, etc.

The new ground-breaking version of G2N Nova offers global, gross-to-net payroll processing capabilities across 100+ countries, making it the world’s most advanced and powerful native payroll engine. G2N Nova is available as a SaaS or service delivery platform that can be used as a stand-alone global payroll platform or deeply integrated with all major HCM or Workforce Management software solutions.

About Mercans

Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll engine G2N Nova enables Enterprise businesses & HCM providers to perform gross to-net calculations across 100+ legislation. To learn more about this innovative platform, visit www.mercans.com

LinkedIn

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123634878/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye